1. Home
  2. SBFM vs PMAX Comparison

SBFM vs PMAX Comparison

Compare SBFM & PMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SBFM
  • PMAX
  • Stock Information
  • Founded
  • SBFM 2006
  • PMAX 2019
  • Country
  • SBFM United States
  • PMAX Hong Kong
  • Employees
  • SBFM N/A
  • PMAX N/A
  • Industry
  • SBFM Biotechnology: Pharmaceutical Preparations
  • PMAX
  • Sector
  • SBFM Health Care
  • PMAX
  • Exchange
  • SBFM Nasdaq
  • PMAX Nasdaq
  • Market Cap
  • SBFM 6.5M
  • PMAX 6.7M
  • IPO Year
  • SBFM N/A
  • PMAX 2024
  • Fundamental
  • Price
  • SBFM $1.40
  • PMAX $0.33
  • Analyst Decision
  • SBFM Strong Buy
  • PMAX
  • Analyst Count
  • SBFM 1
  • PMAX 0
  • Target Price
  • SBFM $15.00
  • PMAX N/A
  • AVG Volume (30 Days)
  • SBFM 41.6K
  • PMAX 182.0K
  • Earning Date
  • SBFM 08-12-2025
  • PMAX 10-17-2025
  • Dividend Yield
  • SBFM N/A
  • PMAX N/A
  • EPS Growth
  • SBFM N/A
  • PMAX N/A
  • EPS
  • SBFM N/A
  • PMAX N/A
  • Revenue
  • SBFM $36,341,741.00
  • PMAX $4,694,079.00
  • Revenue This Year
  • SBFM $32.20
  • PMAX N/A
  • Revenue Next Year
  • SBFM $32.74
  • PMAX N/A
  • P/E Ratio
  • SBFM N/A
  • PMAX N/A
  • Revenue Growth
  • SBFM 19.22
  • PMAX N/A
  • 52 Week Low
  • SBFM $1.17
  • PMAX $0.28
  • 52 Week High
  • SBFM $3.90
  • PMAX $4.70
  • Technical
  • Relative Strength Index (RSI)
  • SBFM 41.45
  • PMAX 36.98
  • Support Level
  • SBFM $1.36
  • PMAX $0.30
  • Resistance Level
  • SBFM $1.52
  • PMAX $0.37
  • Average True Range (ATR)
  • SBFM 0.07
  • PMAX 0.03
  • MACD
  • SBFM -0.00
  • PMAX -0.00
  • Stochastic Oscillator
  • SBFM 25.00
  • PMAX 32.24

About SBFM Sunshine Biopharma Inc.

Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.

About PMAX Powell Max Limited Class A Ordinary Shares

Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.

Share on Social Networks: